ROXRO PHARMA, Inc. is a privately-owned specialty pharmaceutical company focused on the treatment of pain. Founded in 1999, ROXRO in-licenses promising drug candidates for rapid development in acute medical conditions. The company's highly experienced staff engages a global network of external experts to conduct preclinical and clinical studies and to manufacture its drug products.

ROXRO's tratme,t of acute pain is currently in Phase 3 trials, including post-operative pain. It is an intranasal formulation of the broadly used injectible analgesic, ketorolac. ROXRO has successfully completed two Phase 2 trials of the compound in dental and post-operative pain, and one Phase 3 trial in post-operative pain. The second and final Phase 3 trial is currently ongoing.

ROXRO PHARMA is focusing its development and commercialization activities on the US pharmaceutical market. ROXRO plans to establish select partnerships in key geographies and markets to ensure the sales potential of its compounds is maximized.